Intelligence / Healthtech / New Clinical Trials / TripleMed B.V.
Clinicaltrial registered10 Nov 2026
TripleMed B.V.
10 Nov 2026: Trial registered · Safety and Effectiveness Assessment of AneuFix Injectable Polymer Sac Filling to Assure Long-term Durability of EVAR.. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 10 Nov 2026
- Title
- Safety and Effectiveness Assessment of AneuFix Injectable Polymer Sac Filling to Assure Long-term Durability of EVAR.
- Conditions
- Endoleak After Endovascular Aneurysm Repair, Aortic Aneurysm Abdominal
- Phase
- Not applicable
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Netherlands
- Country
- Netherlands
- Reference
- NCT07928505
- Location
- Netherlands
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at TripleMed B.V.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Netherlands
New Clinical Trials
10 NovEli Lilly and Companytrial registered · A Study of Brenipatide in Participants With Major Depressive DisorderClinical5 NovNovo Nordisk A/Strial registered · A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityClinical4 NovBoehringer Ingelheimtrial registered · A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Clinical29 OctSanofitrial registered · A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Netherlands)Clinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.